Related Experiment Videos
Newer cephalosporins: lessons to be learned from clinical trials in intraabdominal infections
1Department of Surgery, University of Minnesota School of Medicine, Minneapolis.
Abstract:
Recent clinical trials testing the efficacy of newer cephalosporins in intraabdominal infections lack a number of the study design criteria proposed by Solomkin et al. Nevertheless, these trials all support the use of these newer cephalosporins in the treatment of intraabdominal infections. These newer agents demonstrate increased in vitro antimicrobial activity against potential aerobic pathogens, which suggests that they may be used in combination with an antianaerobic drug in the treatment of intraabdominal infections. Therefore, agents including cefotaxime, cefoperazone, ceftazidime, cefuroxime, ceftriaxone, and aztreonam may be chosen in place of the standard aminoglycoside. Previous studies have demonstrated the necessity of both aerobic and anaerobic coverage in empiric therapy of intraabdominal infections. Cefotetan, ceftizoxime, cefoxitin, moxalactam, mezlocillin, and piperacillin all have in vitro activity against aerobes and anaerobes (including B. fragilis), thus, these agents have a potential as monotherapy for acute intraabdominal infections in otherwise healthy patients. Directed combination chemotherapy or perhaps imipenem alone is recommended for persistent peritonitis and intraabdominal infections in immunocompromised hosts.
Insights
Newer cephalosporins show promise for treating intra-abdominal infections, offering improved antimicrobial activity. These agents may replace standard aminoglycosides, especially when combined with antianaerobic drugs.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Intra-abdominal infections (IAIs) require broad-spectrum antimicrobial coverage for both aerobic and anaerobic pathogens.
- Traditional treatment regimens often involve aminoglycosides, which have limitations.
- Recent clinical trials have evaluated newer cephalosporins for IAI treatment, though some lack established design criteria.
Purpose of the Study:
- To evaluate the efficacy and potential role of newer cephalosporins in the management of intra-abdominal infections.
- To assess the in vitro antimicrobial activity of newer cephalosporins against common pathogens in IAIs.
- To determine if newer cephalosporins can be used as alternatives to standard therapies, including aminoglycosides.
Main Methods:
- Review of recent clinical trials on cephalosporin efficacy in IAIs.
- Analysis of in vitro antimicrobial activity data for various cephalosporins against aerobic and anaerobic bacteria, including Bacteroides fragilis.
- Comparison of newer cephalosporins with standard treatments like aminoglycosides and combination therapies.
Main Results:
- Newer cephalosporins exhibit enhanced in vitro activity against aerobic pathogens relevant to IAIs.
- Certain cephalosporins (e.g., cefotetan, ceftizoxime, cefoxitin) demonstrate in vitro activity against both aerobes and anaerobes, suggesting potential for monotherapy in specific patient groups.
- Agents like cefotaxime, cefoperazone, ceftazidime, cefuroxime, ceftriaxone, and aztreonam may serve as alternatives to aminoglycosides, often in combination with antianaerobic agents.
Conclusions:
- Newer cephalosporins represent a viable therapeutic option for intra-abdominal infections, offering improved antimicrobial profiles.
- Specific cephalosporins possess activity against both aerobic and anaerobic bacteria, potentially allowing for monotherapy in uncomplicated IAIs.
- For severe or persistent infections, particularly in immunocompromised patients, combination chemotherapy or agents like imipenem remain recommended.